Cerebroprotective effects of RAS inhibitors: Beyond their cardio-renal actions

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 3, 2015, Pages 459-468

  Kalra, Jaspreet ^a   Prakash, Atish ^a,b   Kumar, Puneet ^a   Majeed, Abu Bakar Abdul ^b  

^a ISF COLLEGE OF PHARMACY   (India)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

Author keywords

Alzheimer's disease; bipolar disorder; Brain renin angiotensin system; epilepsy; multiple sclerosis; Parkinson's disease; stroke

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MAS RECEPTOR; MEMBRANE RECEPTOR; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; EPILEPSY; HUMAN; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; BRAIN; DRUG EFFECTS; HEART; KIDNEY; NERVOUS SYSTEM DISEASES; PATHOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALS; BRAIN; HEART; HUMANS; KIDNEY; MODELS, BIOLOGICAL; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84950316978     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320315583582     Document Type: Review

References (109)

1. Ganten D, Boucher R, Genest J,. Renin activity in brain tissue of puppies and adult dogs. Brain Res 1971; 33: 557-559.
2. Ganten D, Marquez-Juli A, Granger P, et al. Renin in dog brain. Am J Physiol 1971; 221: 1733-1737.
3. Von Bohlen und Halbach O, Albrecht D,. The CNS renin-angiotensin system. Cell Tissue Res 2006; 326: 599-616.
4. Kazama K, Anrather J, Zhou P, et al. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res 2004; 95: 1019-1026.
5. Wei Y, Whaley-Connell AT, Chen K, et al. NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension 2007; 50: 384-391.
6. Wright JW, Harding JW,. Brain renin-angiotensin: a new look at an old system. Prog Neurobiol 2011; 95: 49-67.
7. De Bundel D, Smolders I, Vanderheyden P, et al. Ang II and Ang IV: unraveling the mechanism of action on synaptic plasticity, memory, and epilepsy. CNS Neurosci Ther 2008; 14: 315-339.
8. Bild W, Hritcu L, Stefanescu C, et al. Inhibition of central angiotensin II enhances memory function and reduces oxidative stress status in rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2013; 43: 79-88.
9. Labandeira-García JL, Garrido-Gil P, Rodriguez-Pallares J, et al. Brain renin-angiotensin system and dopaminergic cell vulnerability. Front Neuroanat 2014; 8: 67.
10. Moutzouri E, Daios G, Elisaf M, et al. Pharmaceutical modulation of the renin-angiotensin-aldosterone system for stroke prevention: a review of experimental and clinical evidence. CNS Spectr 2010; 15: 619-629.
11. Tsutsumi K, Saavedra JM,. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol 1991; 261 (1 Pt 2): R209-R216.
12. Zhu YZ, Chimon GN, Zhu YC, et al. Expression of angiotensin II AT2 receptor in the acute phase of stroke in rats. Neuroreport 2000; 11: 1191-1194.
13. Gallinat S, Yu M, Dorst A, et al. Sciatic nerve transection evokes lasting up-regulation of angiotensin AT2 and AT1 receptor mRNA in adult rat dorsal root ganglia and sciatic nerves. Brain Res Mol Brain Res 1998; 57: 111-122.
14. Saavedra JM,. Angiotensin II AT1 receptor blockers as treatments for inflammatory brain disorders. Clin Sci 2012; 123: 567-590.
15. Stragier B, Clinckers R, Meurs A, et al. Involvement of the somatostatin-2 receptor in the anticonvulsant effect of angiotensin IV against pilocarpine-induced limbic seizures in rats. J Neurochem 2006; 98: 1100-1113.
16. Lew RA, Mustafa T, Ye S, et al. Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP). J Neurochem 2003; 86: 344-350.
17. Reagan LP, Flanagan-Cato LM, Yee DK, et al. Immunohistochemical mapping of angiotensin type 2 (AT2) receptors in rat brain. Brain Res 1994; 662: 45-59.
18. Roberts KA, Krebs LT, Kramar EA, et al. Autoradiographic identification of brain angiotensin IV binding sites and differential c-Fos expression following intracerebroventricular injection of angiotensin II and IV in rats. Brain Res 1995; 682: 13-21.
19. Rowe BP, Saylor DL, Speth RC, et al. Angiotensin-(1-7) binding at angiotensin II receptors in the rat brain. Regul Pept 1995; 56: 139-146.
20. Rowe BP, Saylor DL, Speth RC,. Analysis of angiotensin II receptor subtypes in individual rat brain nuclei. Neuroendocrinology 1992; 55: 563-573.
21. Song K, Allen AM, Paxinos G, et al. Mapping of angiotensin II receptor subtype heterogeneity in rat brain. J Comp Neurol 1992; 316: 467-484.
22. Zawada W, Mrak RE, Biedermann J, et al. Loss of angiotensin II receptor expression in dopamine neurons in Parkinson's disease correlates with pathological progression and is accompanied by increases in Nox4- and 8-OH guanosine-related nucleic acid oxidation and caspase-3 activation. Acta Neuropathol Commun 2015; 3 (1): 9.
23. Von Bohlen und Halbach O, Walther T, Bader M, et al. Interaction between Mas and the angiotensin AT1 receptor in the amygdala. J Neurophysiol 2000; 83: 2012-2021.
24. Wright JW, Stubley L, Pederson ES, et al. Contributions of the brain angiotensin IVAT4 receptor subtype system to spatial learning. J Neurosci 1999; 19: 3952-3961.
25. Zhuo J, Moeller I, Jenkins T, et al. Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors. J Hypertens 1998; 16 (12 Pt 2): 2027-2037.
26. Zhang H, Ma Q, Zhang YW, et al. Proteolytic processing of Alzheimer's beta-amyloid precursor protein. J Neurochem 2012; 120 (Suppl 1): 9-21.
27. Wright JW, Kawas LH, Harding JW,. A role for the brain RAS in Alzheimer's and Parkinson's diseases. Front Endocrinol 2013; 4: 158.
28. Kehoe PG, Wilcock GK,. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 2007; 6: 373-378.
29. Kramkowski K, Mogielnicki A, Buczko W,. The physiological significance of the alternative pathways of angiotensin II production. J Physiol Pharmacol 2006; 57: 529-539.
30. Wright JW, Harding JW,. Important role for angiotensin III and IV in the brain renin-angiotensin system. Brain Res Brain Res Rev 1997; 25: 96-124.
31. Barnes JM, Barnes NM, Costall B, et al. Angiotensin-converting enzyme inhibition, angiotensin, and cognition. J Cardiovasc Pharmacol 1992; 19 (Suppl 6): S63-S71.
32. Bartus RT, Dean RL 3rd, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-414.
33. Barnes NM, Champaneria S, Costall B, et al. Cognitive enhancing actions of DuP 753 detected in a mouse habituation paradigm. Neuroreport 1990; 1: 239-242.
34. Ellul J, Archer N, Foy CM, et al. The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. J Neurol Neurosurg Psychiatry 2007; 78: 233-239.
35. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
36. Hu J, Igarashi A, Kamata M, et al. Angiotensin converting enzyme degrades Alzheimer amyloid beta-peptide (Dbeta): retards Dbeta aggregation, deposition, fibril formation, and inhibits cytotoxicity. J Biol Chem 2001; 276: 47863-47868.
37. Oba R, Igarashi A, Kamata M, et al. The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur J Neurosci 2005; 21: 733-740.
38. Mogi M, Li JM, Tsukuda K, et al. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun 2008; 375: 446-449.
39. Wang J, Ho L, Chen L, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117: 3393-3402.
40. Takeda S, Sato N, Takeuchi D, et al. Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 2009; 54: 1345-1352.
41. Tota S, Kamat PK, Awasthi H, et al. Candesartan improves memory decline in mice: involvement of AT1 receptors in memory deficit induced by intracerebral streptozotocin. Behav Brain Res 2009; 199: 235-40.
42. Danielyan L, Klein R, Hanson LR, et al. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res. 2010; 13: 195-201.
43. Tsukuda K, Mogi M, Iwanami J, et al. Cognitive deficit in amyloid-β-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-γ activation. Hypertension 2009; 54: 782-787.
44. Ganong WF,. Origin of the angiotensin II secreted by cells. Proc Soc Exp Biol Med 1994; 205: 213-219.
45. Re RN,. Tissue renin-angiotensin systems. Med Clin North Am 2004; 88: 19-38.
46. Gildea JJ,. Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance. Curr Opin Nephrol Hypertens 2009; 18: 28-32.
47. Khan F, Spicarova Z, Zelenin S, Holtback U, Scott L, Aperia A,. Negative reciprocity between angiotensin II type 1 and dopamine D1 receptors in rat renal proximal tubule cells. Am J Physiol Renal Physiol. 2008; 295: F1110-6.
48. Zeng C, Liu Y, Wang Z, et al. Activation of D3 dopamine receptor decreases angiotensin II type 1 receptor expression in rat renal proximal tubule cells. Circ Res 2006; 99: 494-500.
49. Villar-Cheda B, Rodriguez-Pallares J, Valenzuela R, et al. Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease. Eur J Neurosci 2010; 32: 1695-1706.
50. Munoz A, Rey P, Guerra MJ, Mendez-Alvarez E, et al. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 2006; 51: 112-120.
51. Okamura A, Rakugi H, Ohishi M, et al. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 1999; 17: 537-545.
52. Zeng C, Luo Y, Asico LD, et al. Perturbation of D1 dopamine and AT1 receptor interaction in spontaneously hypertensive rats. Hypertension 2003; 42: 787-792.
53. Reardon KA, Mendelsohn FA, Chai SY, Horne MK,. The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease. Aust N Z J Med. 2000; 30: 48-53.
54. Mertens B, Vanderheyden P, Michotte Y, Sarre S,. The role of the central renin-angiotensin system in Parkinson's disease. J Renin Angiotensin Aldosterone Syst. 2010; 11: 49-56.
55. Georgiev VP, Lazarova MB, Petkov VD, et al. Interactions between angiotensin II, GABA and diazepam in convulsive seizures. Neuropeptides 1986; 7: 329-336.
56. Tchekalarova J, Kambourova T, Georgiev V,. Effects of angiotensin III and angiotensin IV on pentylenetetrazol seizure susceptibility (threshold and kindling): interaction with adenosine A(1) receptors. Brain Res Bull 2001; 56: 87-91.
57. Arganaraz GA, Konno AC, Perosa SR, et al. The renin-angiotensin system is upregulated in the cortex and hippocampus of patients with temporal lobe epilepsy related to mesial temporal sclerosis. Epilepsia. 2008; 49: 1348-57.
58. Inaba S, Iwai M, Tomono Y, et al. Exaggeration of focal cerebral ischemia in transgenic mice carrying human Renin and human angiotensinogen genes. Stroke 2009; 40: 597-603.
59. Doyle KP, Simon RP, Stenzel-Poore MP,. Mechanisms of ischemic brain damage. Neuropharmacology 2008; 55: 310-318.
60. Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 1583-1633.
61. Passos-Silva DG, Verano-Braga T, Santos RAS,. Angiotensin-(1-7): beyond the cardio-renal actions. Clin Sci 2013; 124, 443-456.
62. Kagiyama T, Kagiyama S, Phillips MI,. Expression of angiotensin type 1 and 2 receptors in brain after transient middle cerebral artery occlusion in rats. Regul Pept 2003; 110: 241-247.
63. Nishimura Y, Ito T, Saavedra JM,. Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000; 31: 2478-2486.
64. Ito T, Yamakawa H, Bregonzio C, et al. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 2002; 33: 2297-2303.
65. Groth W, Blume A, Gohlke P, et al. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. J Hypertens 2003; 21: 2175-2182.
66. Lu Q, Zhu YZ, Wong PT,. Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats. Neuroreport 2005; 16: 1963-1967.
67. Li J, Culman J, Hortnagl H, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005; 19: 617-619.
68. Mecca AP, O'Connor TE, Katovich MJ, et al. Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion. Exp Physiol 2009; 94: 937-946.
69. Stier CT Jr., Adler LA, Levine S, et al. Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens 1993; 11 (Suppl): S37-S42.
70. Inada Y, Wada T, Ojima M, et al. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997; 19: 1079-1099.
71. Lucius R, Gallinat S, Rosenstiel P, et al. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med 1998; 188: 661-670.
72. Cote F, Do TH, Laflamme L, et al. Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J Biol Chem 1999; 274: 31686-31692.
73. Reinecke K, Lucius R, Reinecke A, et al. Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-kappaB. FASEB J 2003; 17: 2094-2096.
74. Grobe JL, Mecca AP, Lingis M,. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 2007; 292: H736-H742.
75. Grobe JL, Mecca AP, Mao H, et al. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 2006; 290: H2417-H2423.
76. Huentelman MJ, Grobe JL, Vazquez J,. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 2005; 90: 783-790.
77. Ferreira AJ, Jacoby BA, Araujo CA,. The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol 2007; 292: H1113-H1119.
78. Ferreira AJ, Shenoy V, Yamazato Y, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 1048-1054.
79. Ferreira AJ, Santos RA, Almeida AP,. Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 2001; 38 (3 Pt 2): 665-668.
80. Santos RA, Ferreira AJ, Nadu AP,. Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics 2004; 17: 292-299.
81. Petty WJ, Miller AA, McCoy TP, et al. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res 2009; 15: 7398-7404.
82. Mecca AP, Regenhardt RW, O'Connor TE,. Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp Physiol 2011; 96: 1084-1096.
83. Brouns R, De Deyn PP,. The complexity of neurobiological processes in acute ischemic stroke. Clin Neurol Neurosurg 2009; 111: 483-495.
84. Xue M, Del Bigio MR,. Intracerebral injection of autologous whole blood in rats: time course of inflammation and cell death. Neurosci Lett 2000; 283: 230-232.
85. Enzmann DR, Britt RH, Lyons BE, et al. Natural history of experimental intracerebral hemorrhage: sonography, computed tomography and neuropathology. Am J Neuroradiol 1981; 2: 517-526.
86. Jenkins A, Maxwell WL, Graham DI,. Experimental intracerebral haematoma in the rat: sequential light microscopical changes. Neuropathol Appl Neurobiol 1989; 15: 477-486.
87. Gong Y, Hua Y, Keep RF, et al. Intracerebral hemorrhage: effects of aging on brain edema and neurological deficits. Stroke 2004; 35: 2571-2575.
88. Sokol SI, Portnay EL, Curtis JP, et al. Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke. Neurology 2004; 63: 208-213.
89. Garrido-Gil P, Joglar B, Rodriguez-Perez AI, et al. Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease. J Neuroinflammation 2012; 9: 38.
90. Constantinescu CS, Ventura E, Hilliard B, et al. Effects of the angiotensin converting enzyme inhibitor captopril on experimental autoimmune encephalomyelitis. Immunopharmacol Immunotoxicol 1995; 17: 471-491.
91. Lanz TV, Ding Z, Ho PP,. Angiotensin II sustains brain inflammation in mice via TGF-beta. J Clin Invest 2010; 120: 2782-2794.
92. Stegbauer J, Lee DH, Seubert S,. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci U S A 2009; 106: 14942-14947.
93. Platten M, Youssef S, Hur EM,. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci U S A 2009; 106: 14948-14953.
94. Dwivedi Y, Rizavi HS, Roberts RC, et al. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem 2001; 77: 916-928.
95. Yu HS, Kim SH, Park HG, et al. Intracerebroventricular administration of ouabain, a Na/K-ATPase inhibitor, activates tyrosine hydroxylase through extracellular signal-regulated kinase in rat striatum. Neurochem Int 2011; 59: 779-786.
96. Gould TD, Zarate CA, Manji HK,. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry 2004; 65: 10-21.
97. Liu F, Havens J, Yu Q,. The link between angiotensin II-mediated anxiety and mood disorders with NADPH oxidase-induced oxidative stress. Int J Physiol Pathophysiol Pharmacol 2012; 4: 28-35.
98. De Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.
99. Wang JF, Shao L, Sun X, et al. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 2009; 11: 523-529.
100. Frey BN, Valvassori SS, Reus GZ,. Changes in antioxidant defense enzymes after d -amphetamine exposure: implications as an animal model of mania. Neurochem Res 2006; 31: 699-703.
101. Brietzke E, Stertz L, Fernandes BS,. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009; 116: 214-217.
102. Zubenko GS, Nixon RA,. Mood-elevating effect of captopril in depressed patients. Am J Psychiatry 1984; 141: 110-111.
103. Gard PR, Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin Ther Targets 2004; 8: 7-14.
104. Baghai TC, Binder EB, Schule C,. Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol Psychiatry 2006; 11: 1003-1015.
105. Pariante CM, Lightman SL,. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008; 31: 464-468.
106. Watson S, Gallagher P, Ritchie JC, et al. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004; 184: 496-502.
107. Anderson G, Maes M, Berk M,. Inflammation-related disorders in the tryptophan catabolite pathway in depression and somatization. Adv Protein Chem Struct Biol 2012; 88: 27-48.
108. Wakai T, Yoshioka H, Yagi T, et al. Effects of valsartan on neuroprotection and neurogenesis after ischemia. Neuroreport 2011; 22: 385-390.
109. Macedo DS, Medeiros CD, Cordeiro RC,. Effects of alpha-lipoic acid in an animal model of mania induced by d -amphetamine. Bipolar Disord 2012; 14: 707-718.